ID | 1189 |
Name of the vaccine | SF2a-TT15 |
Microbe | Bacteria |
Disease name | Bacillary Dysentery (Shigellosis) |
Name of bacteria | Shigella genus |
Type of vaccine | Conjugate |
Nucleic acid content | DNA |
Age | 18 to 45 years |
Description of the vaccine | Monovalent Synthetic Carbohydrate-based. |
Name of the manufacturer | University of Maryland, Baltimore |
Name of the manufacturing country | United States |
Year of manufacture | 2022 |
Clinical Phase status | Clinical - Suspended |
Bacterial strain | Gram-negative bacteria. |
Efficacy | NA |
Vaccine formulation | Suspension for injection |
Dosage | Two doses, gap of 4 weeks. |
Mechanism of action | Serum SF2a-specific IgG antibodies. |
Route of administration | Intramuscular |
Indications | Prevention of Shigella infection. |
Export | NA |
Approval | NA |
Adjuvant | NA |
Repurposing | NA |
Side effects of vaccine | NA |
Post vaccination | NA |
Dose type | Combination doses |
Interspecies transfer | NA |
PubMed identifier | 33186516 |
Clinical trial number | NCT04078022 |
Reference | NA |
Other name | NA |
Additional Links | NA
|